Generation Bio (GBIO)
Market Price (2/9/2026): $5.36 | Market Cap: $36.1 MilSector: Health Care | Industry: Biotechnology
Generation Bio (GBIO)
Market Price (2/9/2026): $5.36Market Cap: $36.1 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -177% | Weak multi-year price returns2Y Excs Rtn is -111%, 3Y Excs Rtn is -160% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -90 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -590% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -18%, Rev Chg QQuarterly Revenue Change % is -79% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 58% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -744%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -751% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -178% | ||
| High stock price volatilityVol 12M is 925% | ||
| Key risksGBIO key risks include [1] severe financial distress with a high risk of bankruptcy, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -177% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -111%, 3Y Excs Rtn is -160% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -90 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -590% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -18%, Rev Chg QQuarterly Revenue Change % is -79% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 58% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -744%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -751% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -178% |
| High stock price volatilityVol 12M is 925% |
| Key risksGBIO key risks include [1] severe financial distress with a high risk of bankruptcy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Generation Bio (GBIO) stock has lost about 5% since 10/31/2025 because of the following key factors:
1. Mixed Analyst Sentiment and Price Targets. While Generation Bio received some "Buy" ratings, there were also analyst downgrades and lowered price targets for the company during this period. For example, Jefferies downgraded the stock in December 2025, and Wedbush lowered its price target. This created a balanced outlook among investors, preventing a strong upward or downward movement as varying analyst opinions offset each other, leading to a consensus "Hold" rating from some firms as of early 2026.
2. Incremental Progress in Q3 2025 Earnings, Lacking Major Catalysts. Generation Bio reported its Q3 2025 earnings on November 5, 2025, beating analyst estimates for both EPS and revenue and showing a reduced net loss compared to the previous year. However, these positive financial results were likely perceived as incremental for a preclinical-stage biotechnology company and not a significant enough catalyst to drive substantial stock appreciation. There were no major new clinical trial data readouts or significant regulatory milestones announced within this specific period to excite the market.
Show more
1. Mixed Analyst Sentiment and Price Targets. While Generation Bio received some "Buy" ratings, there were also analyst downgrades and lowered price targets for the company during this period. For example, Jefferies downgraded the stock in December 2025, and Wedbush lowered its price target. This created a balanced outlook among investors, preventing a strong upward or downward movement as varying analyst opinions offset each other, leading to a consensus "Hold" rating from some firms as of early 2026.
2. Incremental Progress in Q3 2025 Earnings, Lacking Major Catalysts. Generation Bio reported its Q3 2025 earnings on November 5, 2025, beating analyst estimates for both EPS and revenue and showing a reduced net loss compared to the previous year. However, these positive financial results were likely perceived as incremental for a preclinical-stage biotechnology company and not a significant enough catalyst to drive substantial stock appreciation. There were no major new clinical trial data readouts or significant regulatory milestones announced within this specific period to excite the market.
Show more
Stock Movement Drivers
Fundamental Drivers
The -3.1% change in GBIO stock from 10/31/2025 to 2/8/2026 was primarily driven by a -28.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.51 | 5.34 | -3.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 21 | 15 | -28.1% |
| P/S Multiple | 1.7 | 2.4 | 35.4% |
| Shares Outstanding (Mil) | 7 | 7 | -0.5% |
| Cumulative Contribution | -3.1% |
Market Drivers
10/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| GBIO | -3.1% | |
| Market (SPY) | 1.3% | 13.0% |
| Sector (XLV) | 9.3% | 4.7% |
Fundamental Drivers
The 20.3% change in GBIO stock from 7/31/2025 to 2/8/2026 was primarily driven by a 94.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.44 | 5.34 | 20.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 25 | 15 | -37.8% |
| P/S Multiple | 1.2 | 2.4 | 94.4% |
| Shares Outstanding (Mil) | 7 | 7 | -0.5% |
| Cumulative Contribution | 20.3% |
Market Drivers
7/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| GBIO | 20.3% | |
| Market (SPY) | 9.6% | 12.6% |
| Sector (XLV) | 21.5% | 20.8% |
Fundamental Drivers
The -31.2% change in GBIO stock from 1/31/2025 to 2/8/2026 was primarily driven by a -17.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.76 | 5.34 | -31.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19 | 15 | -17.8% |
| P/S Multiple | 2.8 | 2.4 | -15.5% |
| Shares Outstanding (Mil) | 7 | 7 | -0.9% |
| Cumulative Contribution | -31.2% |
Market Drivers
1/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| GBIO | -31.2% | |
| Market (SPY) | 15.8% | 2.6% |
| Sector (XLV) | 8.8% | 14.6% |
Fundamental Drivers
The -90.9% change in GBIO stock from 1/31/2023 to 2/8/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 59.00 | 5.34 | -90.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 15 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 2.4 | |
| Shares Outstanding (Mil) | 6 | 7 | -12.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/8/2026| Return | Correlation | |
|---|---|---|
| GBIO | -90.9% | |
| Market (SPY) | 76.2% | 5.4% |
| Sector (XLV) | 23.8% | 14.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GBIO Return | -75% | -44% | -58% | -36% | -46% | 1% | -98% |
| Peers Return | 55% | -30% | -26% | -29% | 56% | 6% | -5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| GBIO Win Rate | 33% | 33% | 50% | 42% | 42% | 50% | |
| Peers Win Rate | 52% | 42% | 40% | 37% | 58% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GBIO Max Drawdown | -79% | -48% | -77% | -38% | -96% | -5% | |
| Peers Max Drawdown | -13% | -55% | -47% | -43% | -37% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALNY, ARWR, MRNA, NTLA, BEAM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | GBIO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.7% | -25.4% |
| % Gain to Breakeven | 4296.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -45.1% | -33.9% |
| % Gain to Breakeven | 82.0% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
Compare to ALNY, ARWR, MRNA, NTLA, BEAM
In The Past
Generation Bio's stock fell -97.7% during the 2022 Inflation Shock from a high on 3/1/2021. A -97.7% loss requires a 4296.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Generation Bio (GBIO)
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
AI Analysis | Feedback
Here is an analogy for Generation Bio (GBIO):
- Moderna for gene therapy, but focused on a non-viral DNA platform instead of mRNA.
AI Analysis | Feedback
- Closed-ended DNA (ceDNA) Gene Therapy Platform: This proprietary non-viral gene therapy platform is designed for durable, redosable, and large-payload gene delivery for various genetic diseases.
- Cell-Targeted Lipid Nanoparticle (ctLNP) Delivery System: A key component of their platform that enables efficient and specific delivery of ceDNA to target cells and tissues within the body.
- GBIO-001 (Phenylketonuria Program): A preclinical gene therapy candidate aimed at treating phenylketonuria (PKU), a rare metabolic disorder, by restoring functional phenylalanine hydroxylase (PAH) activity.
- GBIO-002 (Hemophilia A Program): A preclinical gene therapy candidate aimed at treating Hemophilia A, a rare bleeding disorder, by providing durable expression of factor VIII protein.
AI Analysis | Feedback
Generation Bio (GBIO) is a clinical-stage genetic medicines company focused on the research and development of gene therapies. As such, the company does not currently have commercial products on the market and therefore does not have traditional "major customers" in the sense of companies or individuals purchasing products.
However, if its gene therapies are successfully developed, receive regulatory approval, and are commercialized, the ultimate beneficiaries and end-users of these treatments would be individual patients. Therefore, interpreting the prompt in terms of the intended recipients of its therapeutic products, Generation Bio aims to serve categories of individuals.
The up to three categories of individuals that Generation Bio aims to serve are:
- Patients suffering from specific severe genetic disorders: This primary category includes individuals diagnosed with debilitating genetic conditions such as hemophilia A and various inherited retinal diseases, which are currently the focus of Generation Bio's clinical development programs. These individuals seek curative or significantly life-altering treatments where current options are limited or involve chronic management.
- Patients with other monogenic or complex genetic diseases addressable by next-generation gene therapy: As Generation Bio's proprietary non-viral gene therapy platform evolves, it aims to develop treatments for a broader spectrum of genetic conditions beyond its initial pipeline. This category encompasses individuals with other severe inherited disorders that could benefit from durable, cell-free DNA-based gene therapies.
- Individuals seeking long-term or potentially curative therapeutic solutions for genetic diseases: This category highlights individuals who, along with their families and caregivers, are searching for advanced medical interventions that offer the promise of a single-treatment cure or significant, long-lasting therapeutic benefit, thereby reducing the burden of chronic disease management and improving quality of life.
AI Analysis | Feedback
nullAI Analysis | Feedback
Yalonda Howze, JD Interim Chief Executive Officer & President
Ms. Howze was appointed Interim Chief Executive Officer and President of Generation Bio, effective October 31, 2025. She previously served as the company's Chief Legal Officer since April 2023.
Kevin Conway Chief Financial Officer
Mr. Conway serves as the Chief Financial Officer for Generation Bio. Other executives previously held this position, including Matthew Norkunas who was appointed in July 2020, and Tom Graney who was appointed in December 2018. Prior to joining Generation Bio, Tom Graney served as CFO at Vertex Pharmaceuticals and held roles at Ironwood and Johnson & Johnson, including worldwide vice president of finance and CFO for Ethicon Surgical Care.
Geoff McDonough, MD Chair of the Board
Dr. McDonough served as President and Chief Executive Officer of Generation Bio from October 2017 until he stepped down on October 31, 2025, to become Chair of the Board. He co-founded Generation Bio in 2016 with Atlas Venture, which launched the company with a $25 million Series A. Prior to Generation Bio, Dr. McDonough was President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 to 2017. He also held various senior leadership positions at Genzyme Corporation, including President of Genzyme Europe and Senior Vice President and General Manager of the global Lysosomal Storage Diseases business. Dr. McDonough's background includes experience as a physician and as a medical technology entrepreneur.
Matthew Stanton Chief Scientific Officer
Dr. Stanton holds the position of Chief Scientific Officer at Generation Bio. He was identified as Head of Platform Research when the company was founded in 2018.
Doug Kerr Chief Development Officer
Mr. Kerr is the Chief Development Officer at Generation Bio. He was also identified as Head of Preclinical Research and Clinical Development when the company was founded in 2018.
AI Analysis | Feedback
The key risks to Generation Bio's (GBIO) business are primarily centered around its precarious financial health, the inherent uncertainties of biotechnology development, and the risks associated with its recently announced acquisition.
- Poor Financial Health and Liquidity: Generation Bio faces significant financial challenges, including poor financial strength, a Piotroski F-Score of 3 indicating weak business operations, and deeply negative operating and net margins (approximately -589.59% and -410.13% respectively). The company has an Altman Z-Score of -9.1, which places it in a distress zone and suggests a high risk of bankruptcy within two years. Although it maintains strong liquidity with a current ratio of 4.44, it is rapidly burning through its cash reserves, raising concerns about its ability to fund research and development efforts given the extended timelines required for generating patient data.
- High Risks and Uncertainties in Biotechnology Development: As a biotechnology company focused on novel gene therapies, Generation Bio is exposed to substantial risks inherent in drug discovery and development. These include the long and unpredictable timelines for identifying product candidates, conducting preclinical studies and clinical trials, and securing regulatory approvals. The efficacy of its platforms, particularly its non-viral gene therapy, remains unclear, and past failures of its initial ceDNA platform have been noted, even with pivots to newer technologies like immune silent DNA (iqDNA). The complex nature of developing redosable therapeutics that reprogram T cells for autoimmune diseases also presents significant scientific and technical hurdles.
- Acquisition and Related Uncertainties: The announced acquisition of Generation Bio by XOMA Royalty Corporation introduces specific risks. There is uncertainty regarding whether the merger conditions will be satisfied and if the acquisition will close as anticipated. Additionally, there are legal investigations into whether the sale is fair to Generation Bio shareholders and if the company obtained the best possible consideration, or if XOMA is underpaying. Shareholders are also set to receive contingent value rights (CVRs), which involve uncertainties regarding potential future payments.
AI Analysis | Feedback
The rapid advancement and clinical validation of in vivo gene editing technologies delivered via lipid nanoparticles (LNPs) by competing biotechnology companies represent a clear emerging threat. Companies like Intellia Therapeutics, Verve Therapeutics, and Beam Therapeutics are demonstrating progress with gene editing platforms (e.g., CRISPR/Cas9, base editing) that aim to provide a more permanent correction of genetic mutations by directly altering the patient's DNA. While Generation Bio's proprietary ceDNA and ctLNP platform focuses on delivering a functional gene and enabling redosing, the ultimate goal of both approaches is to treat genetic diseases. If in vivo gene editing proves to be safer, more effective, and durable enough to offer a "one-time fix" for a broad range of genetic disorders, it could be perceived as a superior therapeutic modality and significantly diminish the market potential and perceived value of gene addition therapies for certain indications, drawing away investment and patient interest from gene addition platforms.
AI Analysis | Feedback
nullAI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Generation Bio (GBIO) over the next 2-3 years:
- Advancement of siRNA Therapeutics for Autoimmune Diseases: Generation Bio has strategically reorganized to prioritize the development of siRNA therapeutics using its cell-targeted lipid nanoparticle (ctLNP) delivery system, specifically focusing on T cell-driven autoimmune diseases. The company aims to submit its first Investigational New Drug (IND) application for a lead T cell-selective LNP-siRNA program in this area by the second half of 2026. Successful progression through clinical trials and eventual commercialization of these programs would be a significant driver of future revenue.
- Progress in the Immune-Quiet DNA (iqDNA) Platform and Hemophilia A Program: Generation Bio continues to advance its immune-quiet DNA (iqDNA) platform, with a particular focus on its lead program for hemophilia A and other applications. The iqDNA technology, alongside their closed-ended DNA (ceDNA) technology, represents a novel approach to delivering genetic material with potential for redosability and scalability. Positive clinical developments and potential regulatory approval for its hemophilia A program would open up new revenue streams.
- Strategic Collaborations and Partnerships: The company's business model includes generating revenue through strategic partnerships and licensing agreements. Generation Bio has ongoing collaborations with leading pharmaceutical companies, including ModernaTX, Inc., which has contributed to its collaboration revenue. Continued or expanded collaborations and new licensing agreements for its proprietary platforms could provide consistent revenue growth.
- Expansion and Optimization of Proprietary Technology Platforms: Generation Bio's core strength lies in its proprietary non-viral genetic medicine platform, which includes the ctLNP delivery system and ceDNA/iqDNA technology. The company has made advancements in optimizing its LNP delivery system to improve tissue targeting and payload capacity and expanded its ceDNA technology to address a broader range of diseases. Further optimization and broader application of these innovative platforms to new disease areas, or through partnerships, are expected to create additional revenue opportunities.
AI Analysis | Feedback
Share Issuance
- Generation Bio completed its Initial Public Offering (IPO) in June 2020, issuing 12,105,263 shares of common stock at $19.00 per share, which generated approximately $230 million in gross proceeds.
- In July 2025, the company executed a 1-for-10 reverse stock split to increase its per-share market price, reducing the number of outstanding shares from approximately 67.3 million to 6.7 million.
Inbound Investments
- In January 2020, Generation Bio raised $111 million in a Series C funding round, with T. Rowe Price and Wellington as lead investors.
- As of August 2025, Generation Bio is exploring strategic alternatives, including potential sale, partnership, or spinoff of its assets, and has received inbound interest for its technological assets.
Capital Expenditures
- Generation Bio anticipates that its cash, cash equivalents, and marketable securities will fund its operating expenditures and capital expenditure requirements into the second half of 2027.
- In August 2025, the company paid a lump sum of $31.0 million to settle a lease litigation, which extinguished a larger $58.0 million lease liability for a facility in Waltham, MA.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Generation Bio Earnings Notes | 12/16/2025 | |
| Would You Still Hold Generation Bio Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 33.77 |
| Mkt Cap | 5.8 |
| Rev LTM | 574 |
| Op Inc LTM | -278 |
| FCF LTM | -234 |
| FCF 3Y Avg | -257 |
| CFO LTM | -226 |
| CFO 3Y Avg | -196 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.8% |
| Rev Chg 3Y Avg | 51.4% |
| Rev Chg Q | 9.6% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Mgn LTM | -373.4% |
| Op Mgn 3Y Avg | -732.6% |
| QoQ Delta Op Mgn LTM | -17.3% |
| CFO/Rev LTM | -348.5% |
| CFO/Rev 3Y Avg | -562.7% |
| FCF/Rev LTM | -376.8% |
| FCF/Rev 3Y Avg | -583.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.8 |
| P/S | 10.8 |
| P/EBIT | -1.6 |
| P/E | -1.8 |
| P/CFO | -1.8 |
| Total Yield | -17.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -15.4% |
| D/E | 0.1 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.3% |
| 3M Rtn | 24.2% |
| 6M Rtn | 40.4% |
| 12M Rtn | 22.1% |
| 3Y Rtn | -53.9% |
| 1M Excs Rtn | -2.2% |
| 3M Excs Rtn | 6.9% |
| 6M Excs Rtn | 29.2% |
| 12M Excs Rtn | 2.7% |
| 3Y Excs Rtn | -125.2% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research and development of therapeutics that can deliver siRNA, leveraging our ctLNP delivery | 6 | ||||
| Total | 6 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research and development of therapeutics that can deliver siRNA, leveraging our ctLNP delivery | -139 | ||||
| Total | -139 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research and development of therapeutics that can deliver siRNA, leveraging our ctLNP delivery | -127 | ||||
| Total | -127 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research and development of therapeutics that can deliver siRNA, leveraging our ctLNP delivery | 376 | 477 | 294 | 42 | |
| Total | 376 | 477 | 294 | 42 |
Price Behavior
Price Behavior
| Market Price | $5.34 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/12/2020 | |
| Distance from 52W High | -29.7% | |
| 50 Days | 200 Days | |
| DMA Price | $5.49 | $4.97 |
| DMA Trend | up | indeterminate |
| Distance from DMA | -2.7% | 7.4% |
| 3M | 1YR | |
| Volatility | 34.3% | 930.3% |
| Downside Capture | 59.03 | 476.43 |
| Upside Capture | 73.24 | 378.95 |
| Correlation (SPY) | 27.5% | 2.8% |
GBIO Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.20 | 0.07 | 1.00 | 1.34 | 1.33 | 1.95 |
| Up Beta | -1.31 | -0.53 | 2.42 | 1.14 | -3.27 | -0.74 |
| Down Beta | 0.19 | 0.04 | 0.28 | 0.92 | 0.25 | 1.34 |
| Up Capture | -38% | 74% | 95% | 178% | 2711% | 3919% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 18 | 27 | 54 | 108 | 346 |
| Down Capture | -12% | -39% | 95% | 115% | 174% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 22 | 33 | 69 | 140 | 390 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GBIO | |
|---|---|---|---|---|
| GBIO | -35.9% | 924.9% | 0.89 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 14.7% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 2.6% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | 3.1% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | -0.8% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 13.3% |
| Bitcoin (BTCUSD) | -27.1% | 44.7% | -0.57 | 7.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GBIO | |
|---|---|---|---|---|
| GBIO | -54.7% | 423.3% | 0.32 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 12.9% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 7.6% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 3.9% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | -0.3% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 11.5% |
| Bitcoin (BTCUSD) | 16.1% | 58.0% | 0.49 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GBIO | |
|---|---|---|---|---|
| GBIO | -31.9% | 399.8% | 0.32 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 12.2% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 7.5% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | 3.7% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | -0.2% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 10.8% |
| Bitcoin (BTCUSD) | 68.7% | 66.7% | 1.08 | 5.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2025 | -3.3% | 6.7% | 1.9% |
| 8/12/2025 | 63.2% | 57.8% | 48.4% |
| 3/13/2025 | -6.2% | 0.8% | -24.4% |
| 11/6/2024 | -0.8% | -23.7% | -45.8% |
| 8/7/2024 | 8.1% | 5.0% | -1.8% |
| 3/6/2024 | 6.5% | 8.3% | 43.0% |
| 11/9/2023 | 10.6% | 7.7% | 71.2% |
| 8/2/2023 | 0.2% | -4.0% | 6.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 8 | 10 |
| # Negative | 8 | 11 | 9 |
| Median Positive | 6.5% | 8.0% | 42.1% |
| Median Negative | -6.8% | -9.2% | -17.7% |
| Max Positive | 63.2% | 57.8% | 71.2% |
| Max Negative | -11.6% | -23.7% | -45.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.